Items Tagged ‘MAPK/ERK’

January 8th, 2018

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers

By

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical trial.  Based on data from this trial, ulixertinib has received the U.S. Food and Drug Administration’s Fast Track […]

View full entry

Tags: Colon Cancer, ERK inhibitor, Lung Cancer, MAPK/ERK, Melanoma, News, Precision Cancer Medicine, targeted therapy, ulixertinib